Testing effectiveness (Phase 2)Looking for participantsNCT06581640
What this trial is testing
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Who this might be right for
Multiple MyelomaRelapsed/Refractory
The First Affiliated Hospital of Xiamen University 5